Ombitasvir, Paritaprevir and Ritonavir tablets: Technivie

CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.

{m} Entries

Phase
Study Indication or Disease
Study Name
M14-250 AbbVie_IU_icons_outlined_v3 HCV Phase 3 An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) with Ribavirin (RBV) in Adults with Chronic Hepatitis C Virus Genotype 4 Infection in Egypt
M11-665 AbbVie_IU_icons_outlined_v3 HCV Phase 3 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered with Ribavirin (RBV) in Adults with Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-I)
M13-101 AbbVie_IU_icons_outlined_v3 HCV Phase 2 An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous AbbVie or Abbott DAA Combination Study
P15-336 AbbVie_IU_icons_outlined_v3 HCV PMOS Drug use-results survey of paritaprevir/ritonavir/ombitasvir in patients infected with hepatitis C virus genotype 1 in Japan
P15-764 AbbVie_IU_icons_outlined_v3 HCV PMOS Drug use-results survey in patients infected with hepatitis C virus genotype 2